Loading

logo

Journal of Experimental Neurology

ISSN: 2692-2819

Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/Neurol.2.032

Commentary: Use of BACTRAC Proteomic Database-Uromodulin Protein Expression During Ischemic Stroke

Gabriella-Salome K. Armstrong1, Jacqueline A. Frank1,6, Christopher J. McLouth5, Ann Stowe1,4,6, Jill M. Roberts1,6, Amanda L. Trout1,6, Justin F. Fraser1,2,3,4,6, Keith Pennypacker1,4,6,*
  • 1Department of Neurology, University of Kentucky, Lexington, Kentucky, USA
  • 2Department of Neurosurgery, University of Kentucky, Lexington, Kentucky, USA
  • 3Department of Radiology, University of Kentucky, Lexington, Kentucky, USA
  • 4Department of Neuroscience, University of Kentucky, Lexington, Kentucky, USA
  • 5Department of Behavioral Science, University of Kentucky, Lexington, Kentucky, USA
  • 6Center for Advanced Translational Stroke Science, University of Kentucky, Lexington, Kentucky, USA
+ Affiliations - Affiliations

Corresponding Author

Keith R. Pennypacker, keith.pennypacker@uky.edu

Received Date: December 19, 2020

Accepted Date: February 16, 2021

Citation:

Armstrong GK, Frank JA, McLouth CJ, Stowe A, Roberts J, Trout A, et al. Commentary: Use of BACTRAC Proteomic Database-Uromodulin Protein Expression During Ischemic Stroke. J Exp Neurol. 2021;2(1): 29-33.


Copyright: © 2021 Armstrong GK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: Uromodulin (UMOD) is a glycoprotein expressed by the epithelial cells of the thick ascending limb of Henle’s loop in the kidney. Research has shown that increased uromodulin expression may be associated with lower risk of cardiovascular disease in adults. Utilizing the Blood and Clot Thrombectomy Registry and Collaboration (BACTRAC) (clinicaltrials.gov NCT03153683), a continuously enrolling tissue bank, we aimed to examine the associations between serum uromodulin, age, and high BMI (BMI>25) and its relationship to stroke in patients.

Methods: Arterial blood distal and proximal to the thrombus was collected during a thrombectomy procedure using the BACTRAC protocol and sent to Olink (Boston, MA) to determine proteomic expression via proximity extension assay. Uromodulin expression was recorded and analyzed using two tailed T-tests and linear regressions.

Results: The relationship between systemic and intracranial uromodulin, age, high BMI and hypertension were assessed. Systemic and intracranial uromodulin decreased with age (p<0.0001 and r²=0.343, p=0.0416 and r²=0.102) respectively. Systemic uromodulin expression increased with BMI>25 (p=0.014). Presence of hypertension decreased uromodulin’s expression systemically (p=0.018) and intracranially (p=0.007).

Conclusions: Uromodulin was increased significantly in overweight patients, decreased significantly in older patients, and decreased in patients with hypertension. The increase in uromodulin in people with high BMI could be a protective reaction of the kidney to worsening conditions that make ischemic stroke more likely, with a goal of delaying dangerous outcomes. The decreased expression of uromodulin in older adults could be associated with the decline of general kidney function that accompanies aging. Hypertension can contribute to an AKI by decreasing perfusion to the kidney, therefore decreasing kidney function and uromodulin production. Further analyses are needed to understand the role of uromodulin following ischemic stroke.

Keywords

Ischemic Stroke, Uromodulin protein, High Body Mass Index (BMI), Age, Blood and Clot Thrombectomy Registry and Collaboration (BACTRAC)

Recommended Articles

Body Mass Index and Treatment Response in Patients with Cardiac Light-Chain Amyloidosis

Elevated body mass index (BMI) has been associated with an increased risk of cancer and has been shown to have a negative impact on survival in patients with breast, prostate, oral cancer, and leukemia. In plasma cell dyscrasias, obesity has not only been shown to be a risk factor for the development of multiple myeloma, but also has been associated with a higher rate of progression from monoclonal gammopathy of unknown significance (MGUS) to multiple myeloma, and if intervened on, has bee

Commentary on Association between Birth Weight and Risk of Cardiovascular Disease: Evidence from UK Biobank

Cardiovascular disease (CVD) is one of the major causes of death worldwide and poses a huge public health burden [1,2]. Early identification of individuals at risk of cardiovascular disease is crucial to develop effective preventions. The DOHAD hypothesis proposed by Professor Barker et al. states that an abnormal environment

Commentary: Use of BACTRAC Proteomic Database-Uromodulin Protein Expression During Ischemic Stroke

Uromodulin (UMOD) is a glycoprotein expressed by the epithelial cells of the thick ascending limb of Henle’s loop in the kidney. Research has shown that increased uromodulin expression may be associated with lower risk of cardiovascular disease in adults.

Updates of Recent Vinpocetine Research in Treating Cardiovascular Diseases

Vinpocetine was originally discovered and marketed under the trade name Cavinton around 1978. Vinpocetine is a synthetic derivative of the vincamine molecule which is an alkaloid extracted from the periwinkle plant, Vinca minor [1]. It has been clinically used in many Asian and Europe countries for preventing and treating neurological

Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV

Among women living with HIV (WLWH), increases in body weight and body mass index (BMI, kg/m2) have been observed after switching to the antiretroviral therapies (ART) - Integrase Inhibitors (INSTI) and/or Tenofovir Alafenamide (TAF).

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More